Read by QxMD icon Read

Clinical Genitourinary Cancer

Antoine Finianos, Kanika Gupta, Brandon Clark, Samuel J Simmens, Jeanny B Aragon-Ching
BACKGROUND: Men who present with metastatic disease can have de novo or primary progressive disease. We characterized and compared the outcomes between these 2 groups. PATIENTS AND METHODS: A retrospective cross-sectional analysis from a single institution of de novo versus primary progressive metastatic patients during a 2-year consecutive period was undertaken. Patient characteristics such as demographics, Gleason score, duration of hormone sensitivity, and treatment were obtained...
August 31, 2017: Clinical Genitourinary Cancer
Reeta Barua, Alexander Magony, Korosh Khalili, Philippe L Bedard, Aaron R Hansen, Jeremy Lewin
No abstract text is available yet for this article.
August 31, 2017: Clinical Genitourinary Cancer
Malte Rieken, Luis A Kluth, Christian Seitz, Mohammad Abufaraj, Beat Foerster, Romain Mathieu, Pierre I Karakiewicz, Alexander Bachmann, Alberto Briganti, Morgan Rouprê, Mithat Gönen, Shahrokh F Shariat, Veronika Seebacher
BACKGROUND: We sought to externally validate our pathologic nodal staging score (pNSS) model, which allows for quantification of the likelihood that a pathologically node-negative patient will not have lymph node (LN) metastasis after radical prostatectomy for prostate cancer (PCa) in a population-based cohort. PATIENTS AND METHODS: We analyzed data from 50,598 patients treated with radical prostatectomy and pelvic LN dissection using the Surveillance, Epidemiology, and End Results database...
August 24, 2017: Clinical Genitourinary Cancer
Malte W Vetterlein, Thomas Seisen, Jeffrey J Leow, Mark A Preston, Maxine Sun, David F Friedlander, Christian P Meyer, Felix K-H Chun, Stuart R Lipsitz, Mani Menon, Adam S Kibel, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
INTRODUCTION: Knowledge of the comparative oncologic outcomes of histologic variants after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) relies on small case series. We compared the effect of pure squamous cell carcinoma, adenocarcinoma, and neuroendocrine carcinoma compared with pure urothelial carcinoma (PUC) on overall survival (OS) and pathologic tumor, lymph node, and surgical margin status after RC. PATIENTS AND METHODS: Using the National Cancer Database, we retrospectively examined patients undergoing RC for MIBC from 2003 to 2011...
August 24, 2017: Clinical Genitourinary Cancer
David P Nadebaum, Michael S Hofman, Catherine A Mitchell, Shankar Siva, Rodney J Hicks
No abstract text is available yet for this article.
August 23, 2017: Clinical Genitourinary Cancer
Mohammad Abufaraj, Andrea Haitel, Marco Moschini, Kilian Gust, Beat Foerster, Mehmet Özsoy, David D'Andrea, Pierre I Karakiewicz, Morgan Rouprêt, Alberto Briganti, Shahrokh F Shariat
BACKGROUND: We assessed the role of N-cadherin as a prognostic biomarker in patients with invasive bladder cancer (BCa) who had undergone radical cystectomy (RC). PATIENTS AND METHODS: The present retrospective single-center study included 433 BCa patients who had undergone RC and bilateral lymph node dissection. Formalin-fixed paraffin tissue microarrays were stained with an anti-N-cadherin monoclonal mouse antibody. N-cadherin expression was considered positive if any immunoreactivity was detected...
August 15, 2017: Clinical Genitourinary Cancer
Lana Hamieh, Rana R McKay, Xun Lin, Ronit Simantov, Toni K Choueiri
BACKGROUND: Poor-risk patients with metastatic renal-cell carcinoma remain poorly characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive analysis of this patient population, defined by 3 widely used prognostic models, treated with targeted therapy. PATIENTS AND METHODS: We conducted a pooled retrospective analysis of 4736 metastatic renal-cell carcinoma patients treated on phase 2 and 3 clinical trials. Poor-risk patients were defined according to the Memorial Sloan Kettering Cancer Center (MSKCC), International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), and Hudes risk models...
August 12, 2017: Clinical Genitourinary Cancer
Annalisa Guida, Laurence Albiges, Lisa Derosa, Yohann Loriot, Christophe Massard, Karim Fizazi, Bernard Escudier
BACKGROUND: Everolimus (E) and axitinib (A) have been standard treatments for patients with metastatic renal cell carcinoma after failure of first-line therapy (1L) with vascular endothelial growth factor-targeted therapy. This study aims to compare both drugs in a large comprehensive cancer center. METHODS: Patient characteristics and outcome data from all patients with metastatic renal cell carcinoma who received E or A as second-line therapy at Gustave Roussy from April 2007 to May 2015 have been recorded...
August 12, 2017: Clinical Genitourinary Cancer
Juan Chipollini, Sharon Chaing, Charles C Peyton, Pranav Sharma, Laura C Kidd, Anna R Giuliano, Peter A Johnstone, Philippe E Spiess
BACKGROUND: We analyzed the trends in presentation of squamous cell carcinoma (SCC) of the penis and determined the socioeconomic predictors for locally advanced (cT3-cT4) disease in the United States. PATIENT AND METHODS: The National Cancer Database was queried for patients with clinically nonmetastatic penile SCC and staging available from 1998 to 2012. Temporal trends per tumor stage were evaluated, and a multivariable logistic regression model was used to identify predictors for advanced presentation during the study period...
August 12, 2017: Clinical Genitourinary Cancer
Abhishek Maiti, Maryam Nemati-Shafaee, Pavlos Msaouel, Lance C Pagliaro, Eric Jonasch, Nizar M Tannir, Amishi Y Shah
BACKGROUND: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. PATIENTS AND METHODS: Patients with metastatic or unresectable sRCC were eligible for inclusion. Patients received oral capecitabine 800 mg/m(2) twice daily on days 1 to 21 of a 28-day cycle, intravenous gemcitabine 900 mg/m(2) on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15...
August 10, 2017: Clinical Genitourinary Cancer
Marco Allasia, Francesco Soria, Antonino Battaglia, Carlo Gazzera, Marco Calandri, Mirko Parasiliti Caprino, Barbara Lucatello, Andrea Velrti, Mario Maccario, Barbara Pasini, Andrea Bosio, Paolo Gontero, Paolo Destefanis
INTRODUCTION: Management of renal-cell carcinoma (RCC) in patients with Von Hippel-Lindau syndrome (VHL) represents a clinical dilemma: the oncologic outcomes must be weighed against preservation of renal function. Radiofrequency ablation (RFA) is currently used in selected cases for treatment of small-size RCC. The aim of this study was to evaluate the safety, complications, and functional and oncologic outcomes of RFA in the treatment of RCC in VHL patients. PATIENTS AND METHODS: RCCs were treated with ultrasound-guided RFA or with laparoscopic RFA...
August 10, 2017: Clinical Genitourinary Cancer
Aditya Bagrodia, Ranjit Sukhu, Andrew G Winer, Eric Levy, Michael Vacchio, Byron Lee, Eugene J Pietzak, Timothy F Donahue, Eugene Cha, Gopa Iyer, Daniel D Sjoberg, Andrew J Vickers, Jonathan E Rosenberg, Dean F Bajorin, Guido Dalbagni, Bernard H Bochner
BACKGROUND: We evaluated the incidence and effect of thromboembolic events (TEEs) in patients with muscle-invasive bladder cancer treated with preoperative chemotherapy (POC) and radical cystectomy (RC) with pelvic lymph node dissection (PLND). PATIENTS AND METHODS: We performed a retrospective review of all patients who had undergone POC followed by RC plus PLND for muscle-invasive bladder cancer from June 2000 to January 2013 (n = 357). The chemotherapy type (neoadjuvant vs...
August 10, 2017: Clinical Genitourinary Cancer
Ilya Tsimafeyeu, Tatiana Zolotareva, Sergei Varlamov, Ruslan Zukov, Vladislav Petkau, Mikhail Mazhbich, Galina Statsenko, Sufia Safina, Igor Zaitsev, Dina Sakaeva, Alexander Popov, Pavel Borisov, Liubov Vladimirova
BACKGROUND: The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population. PATIENT AND METHODS: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St...
August 9, 2017: Clinical Genitourinary Cancer
Sydney Marsh, Ryan W Walters, Peter T Silberstein
BACKGROUND: Studies of various prostate cancer patient cohorts found men receiving external-beam radiotherapy (EBRT) had higher mortality than men undergoing radical prostatectomy (RP). Conversely, a recent clinical trial showed no survival differences between treatment groups. We used the National Cancer Data Base (NCDB) to evaluate overall survival in intermediate-risk (T2b-T2c or Gleason 7 [grade group II or III] or prostate-specific antigen 10-20 ng/mL) prostate cancer patients undergoing EBRT with or without androgen deprivation therapy (ADT), RP, or no initial treatment...
August 9, 2017: Clinical Genitourinary Cancer
Satoshi Yamamoto, Shinichi Sakamoto, Xu Minhui, Takaaki Tamura, Kotaro Otsuka, Kodai Sato, Marghulan Maimaiti, Shuhei Kamada, Akinori Takei, Miki Fuse, Kouji Kawamura, Takashi Imamoto, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa
INTRODUCTION: Reductions in testosterone concentration play a significant role in the treatment of prostate cancer. We studied the role of testosterone as a prognostic marker for advanced prostate cancer (stage C or higher) treated with primary androgen-deprivation therapy (ADT). PATIENTS AND METHODS: A total of 348 patients were treated using ADT as first-line therapy for prostate cancer at Chiba University Hospital between 1999 and 2016. Of these, 222 patients with advanced prostate cancer (stage C or higher) were enrolled onto this study...
August 3, 2017: Clinical Genitourinary Cancer
Danielle Rodin, Michael Drumm, Rebecca Clayman, Daniela L Buscariollo, Sigolene Galland-Girodet, Alec Eidelman, Adam S Feldman, Douglas M Dahl, Francis J McGovern, Aria F Olumi, Andrzej Niemierko, William U Shipley, Anthony L Zietman, Jason A Efstathiou
BACKGROUND: Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing. PATIENTS AND METHODS: We performed a retrospective review of 551 consecutive patients who had undergone postradical prostatectomy SRT for recurrent prostate cancer from 2000 to 2013...
August 3, 2017: Clinical Genitourinary Cancer
Elizabeth O'Donnell, Sarah C Markt, Rowan Miller, Brandon Bernard, Laurence Albiges, Clair Beard, Christopher Sweeney
BACKGROUND: To our knowledge, no studies have evaluated the association between smoking and stage at diagnosis or survival among men with germ cell tumors (GCTs). We therefore evaluated the association between smoking and GCT presentation and outcomes. METHODS: Electronic medical records of 1161 patients with GCT treated at Dana-Farber Cancer Institute between 1997 and 2013 were reviewed. Outcomes of interest were stage at diagnosis, relapse from clinical stage I (CSI) disease, relapse after first-line chemotherapy, and death from disease...
August 3, 2017: Clinical Genitourinary Cancer
Hakmin Lee, In Jae Lee, Seok-Soo Byun, Sang Eun Lee, Sung Kyu Hong
BACKGROUND: To investigate the feasibility of active surveillance (AS) in biopsy Gleason score (GS) 3 + 4 prostate cancer (PCa), we compared the outcomes of biopsy GS 3 + 3 and 3 + 4 PCa after radical prostatectomy. PATIENTS AND METHODS: We analyzed the data of 1491 patients undergoing radical prostatectomy for biopsy GS 3 + 3 or 3 + 4 PCa who fulfilled the low-risk criteria of the National Comprehensive Cancer Network guidelines regardless of GS. The favorable GS 3 + 4 group was defined as having core involvement ≤ 50%, prostate-specific antigen density ≤ 0...
August 3, 2017: Clinical Genitourinary Cancer
Omar Abdel-Rahman
OBJECTIVES: To validate the prognostic value of the new American Joint Committee on Cancer (AJCC) staging system (eighth edition) among different staging contexts (clinical vs. pathologic). METHODS: Surveillance, Epidemiology, and End Results (SEER) database (2010-2014) was accessed through SEER*Stat program and both AJCC seventh and eighth edition stages were assigned for each patient. Overall and cancer-specific survival analyses according to both editions were conducted through Kaplan-Meier analysis...
August 3, 2017: Clinical Genitourinary Cancer
Elena Sevillano, Lillian Werner, Dominick Bossé, Aly-Khan A Lalani, Stephanie A M Wankowicz, Guillermo de Velasco, Matthew Farina, Kevin Lundgren, Toni K Choueiri, Aranzazu González Del Alba, Joaquim Bellmunt
BACKGROUND: Upper tract urothelial carcinomas (UTUCs) are increasingly recognized as separate malignancies. Additional insight into clinical outcomes and key prognostic factors are needed. OBJECTIVES: To detail outcomes of patients with UTUCs recurring after radical nephroureterectomy (RNU) and to determine a risk score that predicts outcomes of patients with non-lymph node distant metastasis. DESIGN, SETTING, AND PARTICIPANTS: Chart review of all patients who had an extraurothelial recurrence after RNU for UTUC at Dana-Farber Cancer Institute between 2009 and 2014...
August 2, 2017: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"